Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

被引:25
|
作者
Kitasato, Lisa [1 ]
Tojo, Taiki [1 ,2 ]
Hatakeyama, Yuko [2 ]
Kameda, Ryo [1 ]
Hashikata, Takehiro [1 ]
Yamaoko-Tojo, Minako [1 ,3 ,4 ]
机构
[1] Kitasato Univ, Grad Sch Med Sci, Sagamihara, Kanagawa 228, Japan
[2] Kitasato Univ, Sch Med, Dept Cardioangiol, Sagamihara, Kanagawa 228, Japan
[3] Kitasato Univ, Special Dept Cardiac Rehabil & Prevent Cardiovasc, Sch Med, Sagamihara, Kanagawa 228, Japan
[4] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Minami Ku, Sagamihara, Kanagawa 2520373, Japan
关键词
Atherosclerosis; Endothelial function; Cardiovascular disease prevention; OXIDATIVE STRESS GENERATION; IMPAIRED GLUCOSE-TOLERANCE; CROSS-SECTIONAL RELATIONS; CORONARY-HEART-DISEASE; SENSITIVE K+ CHANNEL; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; NITRIC-OXIDE; RISK-FACTORS; INSULIN-SECRETION;
D O I
10.1186/1475-2840-11-79
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients. However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients. These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control
    C. H. Strey
    J. Young
    M. Collier
    C. M. Florkowski
    B. I. Shand
    R. S. Scott
    Diabetologia, 2004, 47 : 1838 - 1846
  • [42] The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control
    Strey, CH
    Young, J
    Collier, M
    Florkowski, CM
    Shand, BI
    Scott, RS
    DIABETOLOGIA, 2004, 47 (10) : 1838 - 1846
  • [43] Postprandial Improvement in Endothelial Function by Brown Rice Diet Intervention in Patients with Type 2 Diabetes Mellitus
    Kondo, Keiko
    Morino, Katsutaro
    Ishikado, Atsushi
    Nakao, Keiko
    Nakagawa, Fumiyuki
    Nikami, Fumio
    Sekine, Osamu
    Nemoto, Ken-Ichi
    Suwa, Makoto
    Matsumoto, Motonobu
    Makino, Taketoshi
    Kashiwagi, Atsunori
    Ugi, Satoshi
    Maegawa, Hiroshi
    DIABETES, 2015, 64 : A208 - A208
  • [44] Pleiotropic effects of mitiglinide for type 2 diabetes mellitus
    Konya, Hiroyuki
    Miuchi, Masayuki
    Ueyama, Takashi
    Konishi, Kosuke
    Kusunoki, Yoshiki
    Kimura, Yuko
    Ida, Suzuk
    Ishikawa, Tetsuya
    Inokuchi, Chie
    Katsuno, Tomoyuki
    Hamaguchi, Tomoya
    Miyagawa, Jun-Ichiro
    Namba, Mitsuyoshi
    DIABETES, 2007, 56 : A561 - A561
  • [45] Pleiotropic Effects of Mitiglinide in Type 2 Diabetes Mellitus
    Konya, H.
    Miuchi, M.
    Konishi, K.
    Nagai, E.
    Ueyama, T.
    Kusunoki, Y.
    Kimura, Y.
    Nakamura, Y.
    Ishikawa, T.
    Inokuchi, C.
    Katsuno, T.
    Hamaguchi, T.
    Miyagawa, J.
    Namba, M.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (06) : 1904 - 1912
  • [46] Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus
    Fonseca, V
    CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (07) : 635 - 641
  • [47] The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications
    Dunning, Beth Elaine
    Gerich, John E.
    ENDOCRINE REVIEWS, 2007, 28 (03) : 253 - 283
  • [48] Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus
    Shah, P
    Vella, A
    Basu, A
    Basu, R
    Schwenk, WF
    Rizza, RA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11): : 4053 - 4059
  • [49] Exenatide improves postprandial hyperglycemia and dyslipidemia in metformin treated patients with type 2 diabetes
    Bunck, Mathijs C.
    Corner, Anja
    Diamant, Michaela
    Eliasson, Bjorn
    Malloy, Jaret L.
    Shaginian, Rimma M.
    Ding, Wei
    Kendall, David M.
    Smith, Ulf
    Yki-Jarvinen, Hannele
    Heine, Robert J.
    Taskinen, Marja-Ritta
    DIABETES, 2008, 57 : A33 - A33
  • [50] Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes
    Ndisang, Joseph Fomusi
    Lane, Nina
    Jadhav, Ashok
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2009, 296 (05): : E1029 - E1041